Equibles does not estimate personal net worth.
Get an email with a short summary when Evolent Health, Inc. publishes a filing, an earnings call transcript or a press release.
Get EVH alertsJohn Johnson is recorded as CFO at Evolent Health, Inc. (EVH). The newest filing on record that lists John Johnson as CFO at Evolent Health, Inc. (EVH) is dated April 29, 2020. Evolent Health, Inc. reported in an 8-K filed November 6, 2025 that John Johnson was appointed Chief Strategy Officer, effective January 1, 2026. The proxy statement of Evolent Health, Inc. reports total compensation of $5,370,671 for John Johnson in fiscal 2025, including a base salary of $541,918. Disclosed compensation is on record for 7 fiscal years. John Johnson has spoken on 23 earnings calls across 1 company, most recently for Evolent Health, Inc. on November 6, 2025. Evolent Health, Inc. is classified in the Health Information Services industry within the Healthcare sector. Other leadership on record at Evolent Health, Inc. includes Frank Williams (Chairman and Board Member), Mr. Williams (Chairman), Richard "Rick" Jelinek (Chairman) and 7 others.
“on January 1, 2026, the Board determined that John Johnson will transition from his current position of Chief Financial Officer, and appointed Mr. Johnson to the position of Chief Strategy Officer of the Company, as of the Effective Date.”
“Q3 revenue of $480 million represented 8% sequential growth versus the second quarter, driven by new launches across both the Performance Suite and the technology and services suite.”
“Q2 adjusted EBITDA of $37.5 million was in the top half of our range, driven by strong results across both our Tech and Services and Performance Suite models. In the Performance Suite, normalized oncology trend of approximately 10.5% continues to be modestly below our initial forecast for the year of 12%.”
“I will comment on four areas this evening before turning to guidance. One, revenue dynamics affecting actual results in the quarter as well as associated PMPM trends.”
“Revenue in Q4 was $646.5 million across an average of $83.5 million product members. Our product membership was up by 4% year-over-year despite a 6% estimated headwind from Medicaid redeterminations.”
“On our second quarter call in early August, we set out an expected margin expansion path at that time for the rest of the year driven by four factors: organic growth, clinical value creation, normalized prevalence and acuity patterns, and new reimbursement rates.”
SEC 8-K
2026-01-01–present
Start not stated–present
Last confirmed April 29, 2020
Health Information Services · Healthcare
CFO
2026-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Evolent Health, Inc. (EVH) | Former Chief Financial Officer; Chief Strategy Officer | $541,918 | $5,370,671 |
| 2024 | Evolent Health, Inc. (EVH) | Chief Financial Officer | $500,000 | $4,814,291 |
| 2023 | Evolent Health, Inc. (EVH) | Chief Financial Officer | $493,333 | $3,530,596 |
| 2022 | Evolent Health, Inc. (EVH) | Chief Financial Officer | $432,292 | $3,186,217 |
| 2021 | Evolent Health, Inc. (EVH) | Chief Financial Officer | $375,000 | $2,544,800 |
| 2020 | Evolent Health, Inc. (EVH) | Chief Financial Officer | $350,000 | $1,488,600 |
| 2019 | Evolent Health, Inc. (EVH) | Chief Financial Officer | $287,500 | $1,039,167 |
